• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于机制的非阿片类镇痛靶点。

Mechanism-based nonopioid analgesic targets.

作者信息

Zeng Xiangsunze, Powell Rasheen, Woolf Clifford J

出版信息

J Clin Invest. 2025 Jun 2;135(11). doi: 10.1172/JCI191346.

DOI:10.1172/JCI191346
PMID:40454476
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12126239/
Abstract

Acute pain management has historically been dominated by opioids, whose efficacy is overshadowed by the risks of addiction, tolerance, and dependence, culminating in the global opioid crisis. To transcend this issue, we must innovate beyond opioid-based μ receptor treatments, identifying nonopioid analgesics with high efficacy and minimal adverse effects. This Review navigates the multifaceted landscape of inflammatory, neuropathic, and nociplastic pain, emphasizing mechanism-based analgesic targets tailored to specific pain conditions. We delve into the challenges and breakthroughs in clinical trials targeting ion channels, GPCRs, and other molecular targets. We also highlight the intricate crosstalk between different physiological systems and the need for multimodal interventions with distinct pharmacodynamics to manage acute and chronic pain, respectively. Furthermore, we explore emerging strategies, including gene therapy, stem cell therapy, cell type-specific neuromodulation, and AI-driven techniques for objective, unbiased pain assessment and research. These innovative approaches are poised to revolutionize pain management, paving the way for the discovery of safer and more effective analgesics.

摘要

急性疼痛管理在历史上一直由阿片类药物主导,但其疗效因成瘾、耐受性和依赖性风险而黯然失色,最终导致了全球阿片类药物危机。为了克服这个问题,我们必须超越基于阿片类药物的μ受体治疗进行创新,寻找高效且副作用最小的非阿片类镇痛药。本综述探讨了炎症性疼痛、神经性疼痛和神经可塑性疼痛的多方面情况,强调针对特定疼痛状况的基于机制的镇痛靶点。我们深入研究了针对离子通道、G蛋白偶联受体(GPCR)和其他分子靶点的临床试验中的挑战与突破。我们还强调了不同生理系统之间复杂的相互作用,以及分别采用具有不同药效学的多模式干预措施来管理急性和慢性疼痛的必要性。此外,我们探索新兴策略,包括基因治疗、干细胞治疗、细胞类型特异性神经调节以及用于客观、无偏倚疼痛评估和研究的人工智能驱动技术。这些创新方法有望彻底改变疼痛管理,为发现更安全、更有效的镇痛药铺平道路。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5ce/12126239/6edaa6ecb865/jci-135-191346-g197.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5ce/12126239/7e6668efe4f7/jci-135-191346-g194.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5ce/12126239/ba036d0871db/jci-135-191346-g195.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5ce/12126239/6dffef8ebaa6/jci-135-191346-g196.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5ce/12126239/6edaa6ecb865/jci-135-191346-g197.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5ce/12126239/7e6668efe4f7/jci-135-191346-g194.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5ce/12126239/ba036d0871db/jci-135-191346-g195.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5ce/12126239/6dffef8ebaa6/jci-135-191346-g196.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5ce/12126239/6edaa6ecb865/jci-135-191346-g197.jpg

相似文献

1
Mechanism-based nonopioid analgesic targets.基于机制的非阿片类镇痛靶点。
J Clin Invest. 2025 Jun 2;135(11). doi: 10.1172/JCI191346.
2
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
3
Novel non-opioid analgesics in pain management.疼痛管理中的新型非阿片类镇痛药。
Pain Manag. 2024 Dec;14(12):641-651. doi: 10.1080/17581869.2024.2442292. Epub 2024 Dec 18.
4
Nonopioid versus opioid agents for chronic neuropathic pain, rheumatoid arthritis pain, cancer pain and low back pain.用于慢性神经性疼痛、类风湿性关节炎疼痛、癌症疼痛和腰痛的非阿片类药物与阿片类药物对比
Pain Manag. 2019 Mar 1;9(2):205-216. doi: 10.2217/pmt-2018-0052. Epub 2019 Jan 25.
5
Multitarget ligands that comprise opioid/nonopioid pharmacophores for pain management: Current state of the science.用于疼痛管理的包含阿片类/非阿片类药效基团的多靶点配体:科学现状。
Pharmacol Res. 2024 Nov;209:107408. doi: 10.1016/j.phrs.2024.107408. Epub 2024 Sep 21.
6
Long-term treatment in chronic noncancer pain: Results of an observational study comparing opioid and nonopioid therapy.慢性非癌性疼痛的长期治疗:一项比较阿片类药物和非阿片类药物治疗的观察性研究结果。
Scand J Pain. 2017 Oct;17:87-98. doi: 10.1016/j.sjpain.2017.07.005. Epub 2017 Aug 7.
7
Short-Acting Opioids Are Associated with Comparable Analgesia to Long-Acting Opioids in Patients with Chronic Osteoarthritis with a Reduced Opioid Equivalence Dosing.在减少阿片等效剂量的情况下,短效阿片类药物与慢性骨关节炎患者的长效阿片类药物具有相当的镇痛效果。
Pain Med. 2018 Nov 1;19(11):2191-2195. doi: 10.1093/pm/pnx245.
8
Multimodal analgesia as an alternative to the risks of opioid monotherapy in surgical pain management.多模式镇痛作为手术疼痛管理中阿片类药物单一疗法风险的替代方案。
J Healthc Risk Manag. 2017 Jul;37(1):24-30. doi: 10.1002/jhrm.21262.
9
Nonopioid Approaches to Pain Management in Chronic Kidney Disease.慢性肾脏病疼痛管理的非阿片类方法
Semin Nephrol. 2021 Jan;41(1):54-67. doi: 10.1016/j.semnephrol.2021.02.006.
10
Exploring the Role of Chronic Pain Clinics: Potential for Opioid Reduction.探讨慢性疼痛诊所的作用:减少阿片类药物的潜力。
Pain Physician. 2018 Nov;21(6):E603-E610.

引用本文的文献

1
Etiological basis for chronic pain genetic variation in brain and dorsal root ganglia cell types.大脑和背根神经节细胞类型中慢性疼痛遗传变异的病因学基础。
medRxiv. 2025 Jul 5:2025.07.03.25330832. doi: 10.1101/2025.07.03.25330832.

本文引用的文献

1
Human assembloid model of the ascending neural sensory pathway.上行神经感觉通路的人类类组装体模型。
Nature. 2025 Apr 9. doi: 10.1038/s41586-025-08808-3.
2
Meningeal regulatory T cells inhibit nociception in female mice.脑膜调节性T细胞抑制雌性小鼠的伤害感受。
Science. 2025 Apr 4;388(6742):96-104. doi: 10.1126/science.adq6531. Epub 2025 Apr 3.
3
Vascular motion in the dorsal root ganglion sensed by Piezo2 in sensory neurons triggers episodic pain.感觉神经元中由Piezo2感知的背根神经节血管运动引发发作性疼痛。
Neuron. 2025 Jun 4;113(11):1774-1788.e5. doi: 10.1016/j.neuron.2025.03.006. Epub 2025 Mar 27.
4
Non-muscle myosin II inhibition at the site of axon injury increases axon regeneration.轴突损伤部位的非肌肉肌球蛋白II抑制作用可增强轴突再生。
Nat Commun. 2025 Mar 26;16(1):2975. doi: 10.1038/s41467-025-58303-6.
5
Differential modification of ascending spinal outputs in acute and chronic pain states.急性和慢性疼痛状态下脊髓上行输出的差异性修饰
Neuron. 2025 Apr 16;113(8):1223-1239.e5. doi: 10.1016/j.neuron.2025.01.031. Epub 2025 Feb 28.
6
Vertex's opioid-free drug for acute pain wins FDA approval.福泰制药公司的急性疼痛无阿片类药物获美国食品药品监督管理局批准。
Nat Biotechnol. 2025 Mar;43(3):287-289. doi: 10.1038/s41587-025-02590-3.
7
Macrophages protect against sensory axon loss in peripheral neuropathy.巨噬细胞可预防周围神经病变中的感觉轴突损失。
Nature. 2025 Apr;640(8057):212-220. doi: 10.1038/s41586-024-08535-1. Epub 2025 Feb 12.
8
Divergent sex-specific pannexin-1 mechanisms in microglia and T cells underlie neuropathic pain.小胶质细胞和T细胞中不同的性别特异性泛连接蛋白-1机制是神经性疼痛的基础。
Neuron. 2025 Mar 19;113(6):896-911.e9. doi: 10.1016/j.neuron.2025.01.005. Epub 2025 Jan 31.
9
How to build the virtual cell with artificial intelligence: Priorities and opportunities.如何利用人工智能构建虚拟细胞:优先事项与机遇
Cell. 2024 Dec 12;187(25):7045-7063. doi: 10.1016/j.cell.2024.11.015.
10
Na1.8 inhibitor poised to provide opioid-free pain relief.钠通道1.8抑制剂有望实现无阿片类药物的疼痛缓解。
Nat Rev Drug Discov. 2025 Jan;24(1):3-5. doi: 10.1038/d41573-024-00203-3.